Asialo von Willebrand factor (AS-vWf) binds to and aggregates normal human platelets in the absence of ristocetin. Maximal specific binding of AS-vWf is 1-2 ug vWf protein/108 platelets.
to normal primary hemostasis, that is, the adhesion of platelets to subendothelial surfaces and the subsequent aggregation of platelets (1, 2) . Human vWf in the presence of ristocetin binds to the glycoprotein lb (GPIb) of platelets that are either intact metabolically or have been fixed with formaldehyde. To date, no in vivo analogue of ristocetin has been found. DeMarco and Shapiro reported, however, that asialo vWf (AS-vWf) binds spontaneously and independently of ristocetin to the platelet surface and causes aggregation (3) . They postulated that this represented a possible mechanism for the in vivo binding of vWf to human platelets and subsequent adhesion and aggregation.
We have undertaken an investigation to determine the site or sites of AS-vWf binding to human platelets, the effects of other plasma proteins on the binding, and the mechanism(s) of platelet aggregation induced by AS-vWf. Our studies employed (a) monoclonal antibodies specific for GPIb and the glycoprotein lIb/Ila complex (GPIIb/IIIa), (b) plasmas containing variable concentrations of fibrinogen, and (c) the platelets from thrombasthenic patients.
Methods
Blood was drawn from normal subjects and patients by use of a twosyringe technique. A 19-gauge needle was used and the initial 5-10 ml of blood was used for other laboratory tests. The blood from the second syringe was placed into polypropylene tubes containing 0.1 ml sodium citrate anticoagulant, final concentration 10.9 mM. Plateletrich plasma (PRP) was prepared from whole blood by removal of the plasma-platelet layer after centrifugation at 750 relative centrifugal force (RCF) for 3 min at 250C. In some experiments, the platelets were washed free of erythrocytes and leukocytes by the preparation of PRP and one wash of the erythrocytes with Hepes buffer, pH 7.35 (4) . The PRP and wash were then placed on a discontinuous arabinogalactan gradient 20% (3 ml) and 10% (5 ml) and platelets were separated from plasma proteins by centrifugation at 2,000 RCF for 30 min. The platelets (>85% recovery) were then resuspended in autologous or homologous normal plasma or plasma from two patients with congenital afibrinogenemia. Plasma was obtained from two patients with congenital afibrinogenemia who had thrombin time > 300 s, and no detectable fibrinogen by the Clauss technique or tanned erythrocyte hemagglutination inhibition, i.e., a level < 0.5 isg/ml. Mixing studies were performed to ensure that neither afibrinogenemic plasma contained antifibrinogen antibodies. Each afibrinogenemic plasma was incubated with normal plasma samples (1:1 ratio) at 1 and 60 min and were analyzed for fibrinogen content by the method of Clauss and for fibrinogen antigen content by radial immunodiffusion or tanned erythrocyte hemagglutination inhibition. Normal plasma diluted with normal from human cryoprecipitate by chromatography on Sepharose 4B. The ascending limb of the protein peak of the void volume was collected, concentrated by ammonium sulfate precipitation, dialyzed, and used as previously described (7) . Labeling of the protein was performed either by use of the technique of limited oxidation of terminal galactose residues by galactose oxidation and reduction of these residues by tritiated [3H]potassium borohydride as previously described (7), or by iodination with 125I by means of immobilized lactoperoxidase (8, 9) .
Fibrinogen was purified from normal plasma by ammonium sulfate precipitation and further purified on DEAE cellulose chromatography as previously described (10) (12) with N-acetyl neuraminic acid as the standard. The sialic acid released from the FVIII/vWf protein by neuraminidase was assayed by the same method, except that the acid hydrolysis step was omitted (12) .
Glyoxyl agarose electrophoresis. Multimeric structure of the intact and AS-vWf protein before and after radiolabeling was analyzed by glyoxyl agarose electrophoresis and radioautography (13) . The antibody used was a rabbit anti-human FVIII/vWf antibody which had been immunoaffinity purified. In some studies '25I-AS-vWf was used in the binding studies for analysis of the multimeric structure of plateletbound ligand. The platelets were lysed with 30 zd of Tris-EDTAsodium dodecyl sulfate (SDS) buffer, pH 8.0 (10 mM Tris HCI, 1 mM EDTA containing 5% SDS). The samples were incubated for 20 min at 60'C and the extracted '25I-AS-vWf protein was analyzed by glyoxyl agarose electrophoresis and radioautography.
Monoclonal antibodies. Purified IgG or the F(abY2 fragment of three monoclonal antibodies was used in the study. The first monoclonal antibody, 6D1, had previously been characterized as a monoclonal antibody against the GPIb complex that totally blocks ristocetininduced platelet aggregation (14) . The second monoclonal antibody, IOE5, has been characterized as being directed against GPIIb/IIIa and totally blocks fibrinogen binding to platelets (15) . The third monoclonal antibody used in the study is directed against T lymphocyte antigen and did not react with platelets (Bethesda Research Laboratories, Gaithersburg, MD). This monoclonal antibody was used as a control.
All three monoclonal antibodies were tested at doses ranging from 2 b) . After reduction, however, a single subunit of -230,000 mol wt was seen with both preparations (Fig. 2, a and b) . The subunit of the AS-vWf always migrated faster than that of the intact vWf; however, the molecular weight determinations were always within 5,000 (Fig. 2) with a '251-rabbit anti-vWf antibody as previously described (13) .
The anode is at the bottom. Note the mild shift of the migration of the multimers of the AS-vWf protein (lane 4) as compared with intact vWf (lane 3). This shift is a result of the change in molecular weight of the multimers by removal of the sialic acid.
1 U defined as the activity of 1 ml of plasma). Radiolabeling did not affect the specific biologic activity.
Aggregation of platelets by AS-vWf The addition of ASvWf to normal PRP induced platelet aggregation. At lower doses of AS-vWf, the aggregation had a biphasic pattern, but at higher doses, there was only a single major wave of aggregation. In four time-course experiments, when 2-6 ug/ ml of AS-vWf was added to normal PRP, 63% (range, 56-74%) of the AS-vWf bound to the platelets within the first minute. The onset of aggregation was directly related to the amount of AS-vWf bound to the platelets. In four experiments, aggregation began when a mean of 0.174 jig/ml AS-vWf bound to l0o platelets (n = 4; range 0.156 to 0.183) (Fig. 3) . More than 83% of the total AS-vWf present in the reaction mixture was bound at the onset of aggregation (n = 4; range 80-87%). Platelets separated from plasma proteins by the arabinogalactan gradient and resuspended in homologous or autologous plasma behaved identically to PRP, whereas the arabinogalactan- The multimeric structure of the AS-vWf bound to and eluted from the platelets was similar to that of the AS-vWf added to the platelets (Fig. 7) .
Studies with monoclonal antibodies. The AS-vWf concentrations were 3.5 and 7.0 Mg/ml in studies of the inhibition of binding by the monoclonal antibody. The 6D1 antibody, directed against GPIb, totally inhibited the binding of AS-vWf to normal platelets and blocked platelet aggregation at 10 ,ug/ ml final concentration (Fig. 8) . In contrast, the lOE5 antibody, directed against GPIIb/IIIa blocked only 44% of the AS-vWf binding to normal platelets, even when the antibody concen- tration was as high as 73 ,g/ml. Although the inhibition of AS-vWf was only partial, inhibition of platelet aggregation was complete at this concentration of lOE5. At lower concentrations of lOE5 (5.8 ug/ml) AS-vWf binding remained inhibited to nearly the same extent (42%), but platelet aggregation did occur. At even lower concentrations, there was less inhibition of the binding of the AS-vWf and the initial slope of aggregation increased. In contrast, with 6D1 at 0.22 ug/ml, AS-vWf binding was inhibited 58% but aggregation still occurred (Fig.  7) . Compared on a molar basis, the inhibition of binding of AS-vWf was similar when purified IgG and F(abY2 fragments were used. When AS-vWf concentrations were used to achieve saturation, the 6D1 antibody still inhibited 100% of the binding of the AS-vWf protein to normal platelets, whereas lOE5 inhibited 36% (0.51 ;g/108) of the AS-vWf binding (Table I) .
With thrombasthenic platelets, 6D1 again inhibited 100% of the binding of AS-vWf, but lOE5 had only a minimal effect, centrations of AS-vWf protein were added to 0.8 X 108 platelets in an aggregometer at 37°C. After 15 min, the platelets were separated and specific binding was determined as above. The curves shown represent specific binding. Table I , 6D1 is against GPIb. * As in Table I , IOE5 is against GPIIb/IIIa. § Two experiments performed.
"Normal and thrombasthenic PRP were used at 200,000 ,l.
inhibiting just 7-8% of the binding (Table II) . In afibrinogenemic plasma, 6D1 10-12% of that in normal plasma containing fibrinogen.
It was paradoxical that inhibition of platelet aggregation became incomplete when the concentration of lOE5 antibody was decreased from 11.6 to 5.8 gg/ml even though the inhibition of the binding of AS-vWf was only minimally altered. The probable explanation is that reducing the lOE5 concentration permitted the exposure of a small fraction of the GPIIb/IIIa sites to which fibrinogen, but not vWf, bound. This is consistent with studies we and others have reported showing that fibrinogen competes effectively with vWf for these sites (19) (20) (21) .
Our current data extend the previously reported findings of the site of vWf binding to platelets. Ristocetin-induced vWf binding is to the GPIb and can be blocked only by the antibody against GPIb (14, 20, 22, 23) . No effect was seen with the GPIIb/IIIa antibody (19, 20) . Intact vWf binds to platelets independently of ristocetin when the platelets are stimulated with thrombin, ADP, or the combination of ADP and epinephrine (19, 20, (24) (25) (26) . This binding appears to be uniquely to GPIIb/IIIa, since the antibody to GPIb does not inhibit binding or aggregation and both the antibody to GPIIb/ Illa and plasma fibrinogen can effectively and totally inhibit the binding (19) (20) (21) . The binding of the AS-vWf protein appears to be unique in that it initially binds to GPIb, which then modifies the platelet to expose GPIIb/IIIa. Both AS-vWf and fibrinogen can bind to this site, and significant platelet aggregation seems to require that this site be occupied in part by fibrinogen. Studies with the monoclonal antibodies, thrombasthenic platelets, and afibrinogenemic plasma support this concept. We cannot state from our results whether AS-vWf and fibrinogen have structural homologies that are recognized on a common site of the GPIIb/IIIa (27), but even if they did have such a site one would have to postulate another site on AS-vWf that interacts with the GPIb.
The physiologic role, if any, for AS-vWf remains speculative. Since only relatively small amounts of AS-vWf were required to initiate aggregation (-0.17 ,ug/108 platelets representing <2% of the amount of vWf present in 1 ml of normal plasma), it is conceivable that desialation by enzymes on the surface of, or released by, platelets or other cells could generate a physiologically significant amount of AS-vWf. Direct confirmation of an event like this will be required, however, before any such mechanism can be accepted.
